Abstract
Aims: To estimate costs of multiple sclerosis (MS) in a German cohort according to severity of the disease and clinical symptoms. Methods: 144 patients were recruited from an MS outpatient clinic. Costs were calculated according to current German health-economic guidelines from the perspective of the social health insurance system. Patients were either interviewed or completed a questionnaire. Cost assessment covered a 3-month period. Health outcomes were: Expanded Disability Status Scale, MS Functional Composite, Functional Assessment of MS, fatigue, depression (Beck Depression Inventory II) and patients’ socioeconomic status. Multivariate linear regression identified independent cost predictors. Results: Total quarterly costs per patient were EUR 10,329 (95% CI 9,357–11,390). Direct costs were EUR 5,344 for the social health insurance system and EUR 140 for the patient. Drugs represented the major share of direct costs (and 35% of total costs); indirect costs accounted for 47% of total costs. Univariate and multivariate analyses identified age, disability, fatigue and depression as independent predictors for total, indirect or drug costs. Conclusion: MS represents a high economic burden, with direct costs exceeding indirect costs. To reduce costs, research should focus on prevention that slows down progression of MS. Rehabilitation and symptomatic treatment may have merits in decreasing indirect costs.
References
1.
Pugliatti M, Rosati G, Carton H, Riise T, Drulovic J, Vecsei L, et al: The epidemiology of multiple sclerosis in Europe. Eur J Neurol 2006;13:700–722.
2.
Flachenecker P, Stuke K, Elias W, Freidel M, Haas J, Pitschnau-Michel D, et al: Multiple sclerosis registry in Germany: results of the extension phase 2005/2006. Dtsch Arztebl Int 2008;105:113–119.
3.
Trojano M, Paolicelli D, Bellacosa A, Cataldo S: The transition from relapsing-remitting MS to irreversible disability: clinical evaluation. Neurol Sci 2003;24(suppl 5):S268–S270.
4.
McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD, et al: Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001;50:121–127.
5.
Jose Sa M: Psychological aspects of multiple sclerosis. Clin Neurol Neurosurg 2008;110:868–877.
6.
Winkelmann A, Engel C, Apel A, Zettl UK: Cognitive impairment in multiple sclerosis. J Neurol 2007;254(suppl 2):II35–II42.
7.
Ziemssen T: Multiple sclerosis beyond EDSS: depression and fatigue. J Neurol Sci 2009;277(suppl 1):S37–S41.
8.
Confavreux C, Vukusic S: Natural history of multiple sclerosis: a unifying concept. Brain 2006;129:606–616.
9.
Flachenecker P, Rieckmann P: Health outcomes in multiple sclerosis. Curr Opin Neurol 2004;17:257–261.
10.
Kobelt G: Economic evidence in multiple sclerosis: a review. Eur J Health Econ 2004;5(suppl 1):S54–S62.
11.
Bakhshai J, Bleu-Laine R, Jung M, Lim J, Reyes C, Sun L, et al: The cost effectiveness and budget impact of natalizumab for formulary inclusion. J Med Econ 2010;13:63–69.
12.
Putzki N, Fischer J, Gottwald K, Reifschneider G, Ries S, Siever A, et al: Quality of life in 1000 patients with early relapsing-remitting multiple sclerosis. Eur J Neurol 2009;16:713–720.
13.
Kobelt G, Berg J, Lindgren P, Elias WG, Flachenecker P, Freidel M, et al: Costs and quality of life of multiple sclerosis in Germany. Eur J Health Econ 2006;7(suppl 2):S34–S44.
14.
Confavreux C, Vukusic S: Age at disability milestones in multiple sclerosis. Brain 2006;129:595–605.
15.
Naci H, Fleurence R, Birt J, Duhig A: Economic burden of multiple sclerosis: a systematic review of the literature. Pharmacoeconomics 2010;28:363–379.
16.
Polman CH, Reingold SC, Edan G, Filippi M, Hartung HP, Kappos L, et al: Diagnostic criteria for multiple sclerosis: 2005 revisions to the ‘McDonald Criteria’. Ann Neurol 2005;58:840–846.
17.
Kurtzke JF: Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444–1452.
18.
Fischer JS, Rudick RA, Cutter GR, Reingold SC: The Multiple Sclerosis Functional Composite Measure (MSFC): an integrated approach to MS clinical outcome assessment. National MS Society Clinical Outcomes Assessment Task Force. Mult Scler 1999;5:244–250.
19.
Modified Fatigue Impact Scale: Multiple Sclerosis Council for clinical Practice Guidelines: Fatigue and multiple sclerosis: evidence-based management strategies for fatigue in multiple sclerosis, Washington, Paralyzed Veterans of America, 1998.
20.
Tellez N, Rio J, Tintore M, Nos C, Galan I, Montalban X: Does the Modified Fatigue Impact Scale offer a more comprehensive assessment of fatigue in MS? Mult Scler 2005;11:198–202.
21.
Flachenecker P, Kumpfel T, Kallmann B, Gottschalk M, Grauer O, Rieckmann P, et al: Fatigue in multiple sclerosis: a comparison of different rating scales and correlation to clinical parameters. Mult Scler 2002;8:523–526.
22.
Beck AT, Steer RA, Ball R, Ranieri W: Comparison of Beck Depression Inventories-IA and -II in psychiatric outpatients. J Pers Assess 1996;67:588–597.
23.
Cella DF, Dineen K, Arnason B, Reder A, Webster KA, Karabatsos G, et al: Validation of the functional assessment of multiple sclerosis quality of life instrument. Neurology 1996;47:129–139.
24.
EuroQol-Group: EuroQol – a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy 1990;16:199–208.
25.
Greiner W, Claes C, Busschbach JJ, Graf von der Schulenburg JM: Validating the EQ-5D with time trade off for the German population. Eur J Health Econ 2004;6:124–130.
26.
Greiner W: Die Berechnung von Kosten und Nutzen im Gesundheitswesen; in Schöffski O, Graf von der Schulenburg JM (eds): Gesundheitsökonomische Evaluationen. Hamburg, Springer, 2000.
27.
Hamer HM, Spottke A, Aletsee C, Knake S, Reis J, Strzelczyk A, et al: Direct and indirect costs of refractory epilepsy in a tertiary epilepsy center in Germany. Epilepsia 2006;47:2165–2172.
28.
Spottke AE, Reuter M, Machat O, Bornschein B, von Campenhausen S, Berger K, et al: Cost of illness and its predictors for Parkinson’s disease in Germany. Pharmacoeconomics 2005;23:817–836.
29.
Bundesverband der pharmazeutischen Industrie: Rote Liste. Weinheim, Rote Liste, 2006.
30.
Bundesministerium der Justiz: Sozialgesetzbuch I–XI. Köln/Limburg, Bundesanzeiger, 2003.
31.
Krauth C, Hessel F, Hansmeier T, Wasem J, Seitz R, Schweikert B: Empirical standard costs for health economic evaluation in Germany – a proposal by the working group methods in health economic evaluation. Gesundheitswesen 2005;67:736–746.
33.
Graf von der Schulenburg JM, Greiner W, Jost F, Klusen N, Kubin M, Leidl R, et al: German recommendations on health economic evaluation: third and updated version of the Hanover Consensus. Value Health 2008;11:539–544.
34.
Barber JA, Thompson SG: Analysis of cost data in randomized trials: an application of the non-parametric bootstrap. Stat Med 2000;19:3219–3236.
35.
World Medical Association declaration of Helsinki: Recommendations guiding physicians in biomedical research involving human subjects. JAMA 1997;277:925–926.
36.
Kappos L: Effect of drugs in secondary disease progression in patients with multiple sclerosis. Mult Scler 2004;10(suppl 1):S46–S54; discussion S-5.
37.
Reese JP, Winter Y, Balzer-Geldsetzer M, Bötzel, K, Eggert, K, Oertel WH, et al: Morbus Parkinson: Krankheitskosten einer ambulanten Patientenkohorte. Gesundheitswesen 2011;73:22–29.
38.
Happe S, Reese JP, Stiasny-Kolster K, Peglau I, Mayer G, Klotsche J, et al: Assessing health-related quality of life in patients with restless legs syndrome. Sleep Med 2009;10:295–305.
39.
Murphy N, Confavreux C, Haas J, Konig N, Roullet E, Sailer M, et al: Economic evaluation of multiple sclerosis in the UK, Germany and France. Pharmacoeconomics 1998;13:607–622.
40.
Kobelt G, Lindgren P, Smala A, Bitsch A, Haupt M, Kölmel HW, et al: Costs and Quality of life in multiple sclerosis: an observational study in Germany. Eur J Health Econ 2001;2:60–68.
41.
Zeller JW: Immuntherapeutika und Zytostatika; in Schwabe U, Pfaffrath D (eds): Arzneiverordnungreport 2009. Heidelberg, Springer, 2010, pp 621–635.
42.
Ehret R, Balzer-Geldsetzer M, Reese JP, Dodel I, Becker E, Christopher A, et al: Direct costs for Parkinson’s treatment in private neurology practices in Berlin. Nervenarzt 2009;80:452–458.
43.
Kappos L, Polman CH, Freedman MS, Edan G, Hartung HP, Miller DH, et al: Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. Neurology 2006;67:1242–1249.
44.
Devonshire V, Lapierre Y, Macdonell R, Ramo-Tello C, Patti F, Fontoura P, et al: The Global Adherence Project (GAP): a multicenter observational study on adherence to disease-modifying therapies in patients with relapsing-remitting multiple sclerosis. Eur J Neurol 2011;18:69–77.
45.
Tappenden P, McCabe C, Chilcott J, Simpson E, Nixon R, Madan J, et al: Cost-effectiveness of disease-modifying therapies in the management of multiple sclerosis for the medicare population. Value Health 2009;12:657–665.
46.
Lonergan R, Kinsella K, Duggan M, Jordan S, Hutchinson M, Tubridy N: Discontinuing disease-modifying therapy in progressive multiple sclerosis: can we stop what we have started? Mult Scler 2009;15:1528–1531.
47.
Kesselring J, Beer S: Symptomatic therapy and neurorehabilitation in multiple sclerosis. Lancet Neurol 2005;4:643–652.
48.
Patwardhan MB, Matchar DB, Samsa GP, McCrory DC, Williams RG, Li TT: Cost of multiple sclerosis by level of disability: a review of literature. Mult Scler 2005;11:232–239.
49.
McCrone P, Heslin M, Knapp M, Bull P, Thompson A: Multiple sclerosis in the UK: service use, costs, quality of life and disability. Pharmacoeconomics 2008;26:847–860.
50.
Taylor B, McDonald E, Fantino B, Sedal L, MacDonnell R, Pittas F, et al: The cost of multiple sclerosis in Australia. J Clin Neurosci 2007;14:532–539.
51.
Gustavsson A, Svensson M, Jacobi F, Allgulander C, Alonso J, Beghi E, Dodel R, Ekman M, Faravelli C, Fratiglioni L, Gannon B, Jones DH, Jennum P, Jordanova A, Jönsson L, Karampampa K, Knapp M, Kobelt G, Kurth T, Lieb R, Linde M, Ljungcrantz C, Maercker A, Melin B, Moscarelli M, Musayev A, Norwood F, Preisig M, Pugliatti M, Rehm J, Salvador-Carulla L, Schlehofer B, Simon R, Steinhausen HC, Stovner LJ, Vallat JM, Van den Bergh P, van Os J, Vos P, Xu W, Wittchen HU, Jönsson B, Olesen J; on behalf of the CDBE2010 study group: Cost of disorders of the brain in Europe 2010. Eur Neuropsychopharmacol 2011;21:718–779.
© 2011 S. Karger AG, Basel
2011
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.
